Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study - Wikidata - wikimedia - TriplyDB

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study

http://www.wikidata.org/entity/Q33485003

about

Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Axitinib plasma pharmacokinetics and ethnic differences.Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study.Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.

P2860

Q27003304-95CB6A8C-39D3-4729-87A1-888A01FEE99C Q27853203-3F1035B0-6CA6-47E6-A01B-C3D8AE0B01EA Q28547506-60163931-A61A-4430-AE99-1C9250500D73 Q33430139-31B474A2-E5BC-46CD-BCA9-1F260F973198 Q33754122-FD186B33-7BE2-4AD6-8F43-90553343D137 Q34602155-BAE34136-FEFA-432C-9E1A-4442B11C4433 Q34657590-274CE0AF-4FB4-421E-9FCD-729FB32AE874 Q35043936-83D3906D-A83B-4F13-8E41-DFF199C037A5 Q35063752-C47EBA6E-08CA-48ED-95A0-E8F386FE99B1 Q35591889-3AA80926-78BE-4EA1-A055-9A13F10C2124 Q35599769-21D26A70-6E53-431B-ADA5-4A60680515B3 Q35811446-DD8C435B-0630-448E-A478-486ED7E02AF5 Q36153108-DF32FB39-90B2-48CD-9A47-70A5B4E2A366 Q36546814-1CE6C5A5-92FC-49F3-8FA9-976794A8CE88 Q36907986-0E5AA2A0-1E1C-43F1-85B4-4AE390E712B1 Q37226025-42F7C70F-4CB5-40FD-8270-D6D9EF910B0E Q37387563-829D3D91-8CDB-454E-B634-96EEC816489F Q37650644-39BF8980-B03F-43D9-8088-C3ECD0CFB028 Q38076349-2F0AD7E7-6AF7-465A-9D5E-FC61538AA303 Q38348548-5120718F-B1F1-4E5B-8682-46169850D341 Q38531928-FD9FEDD8-AAF4-44C5-A812-EFCB3C5E2C4C Q38867811-F4285194-031D-4828-8F45-3582D5C694A4 Q39100001-FFC74192-ECA7-4F4C-8BFA-4AB9FC5882A8 Q39701786-9AA13681-45E4-48E2-830B-5DCAE8710AF7 Q41092089-1647D6D4-3195-4775-95CD-B9ACA540BB75 Q42014192-F3A4329F-6C91-4BBB-94EC-F9B166247112 Q43785033-2ED1FAA5-5C77-452D-9719-0AD63C450140

P2860

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study

http://www.wikidata.org/entity/Q33485003

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Efficacy of sorafenib on metas ...... sults from a multicenter study

@ast

Efficacy of sorafenib on metas ...... sults from a multicenter study

@en

type

label

Efficacy of sorafenib on metas ...... sults from a multicenter study

@ast

Efficacy of sorafenib on metas ...... sults from a multicenter study

@en

prefLabel

Efficacy of sorafenib on metas ...... sults from a multicenter study

@ast

Efficacy of sorafenib on metas ...... sults from a multicenter study

@en

P1433

Q33485003-E340ACAA-81B3-43A0-903A-4BCBBBCFD4C3

P1476

Q33485003-3FEA8B8A-6CCC-40F9-99AF-EA911DB3F139

P2093

Q33485003-30F9E4D4-D17B-4861-B8E3-CC7164DDDF0C

Q33485003-45229A3B-D0FD-4211-B76C-0D0E77220CF1

Q33485003-5783B199-1C78-44AB-A229-6CC36B17E4B7

Q33485003-67E482FF-BF79-4014-9AEF-4DC819CB5218

Q33485003-90DF41F2-280D-46E8-BCDA-6530BA0B2FF6

Q33485003-9B9DCC62-A9B3-4667-A8B8-3AD24D97DAD5

Q33485003-B716C7DC-C92E-49B9-9F38-15349073B80C

Q33485003-BEEA4489-108C-4B5F-81B2-636CED233B76

Q33485003-F52CA0D0-9CEB-4034-9B27-771F13EF5242

P2860

Q33485003-025A49FD-97FB-43C2-BA68-10E851AED8E1

Q33485003-1847243E-5BD5-4F12-9A0B-FBAA43DB6F9E

Q33485003-24A717DC-F35A-431C-8BDF-4289C290EF87

Q33485003-31B9E5C9-72A9-41F2-B213-E571FD0CE284

Q33485003-4D6EB846-BE15-4E7B-BA1B-693B5D63CEB5

Q33485003-50F53C9B-E701-4771-9318-99C452402DFA

Q33485003-59B64243-1CF4-44A5-9482-76779961470D

Q33485003-59EF40B1-DB91-43D6-B734-5E44853DB781

Q33485003-61AC7737-27D8-48D1-B0E7-E4E1B94BC67C

Q33485003-639DE43E-2BEE-4A5B-88BF-1CF60C6CD2B6

P2888

Q33485003-11853B9E-E662-4EC8-B2FE-3B31398BC44E

P304

Q33485003-7658D52F-8AED-4238-88D0-AC791008E0EA

P31

Q33485003-0FF1B638-598D-4C39-BFE6-8FBBE07AD18F

P356

Q33485003-06A70D4A-48E6-4627-BDA2-BA239137D3BF

P407

Q33485003-6B7B196C-6710-4497-8195-8D39B17C44BC

P478

Q33485003-10C07ADD-1106-4119-A8E0-84C8234839A5

P50

Q33485003-FA317ED9-320C-43B0-9269-A27DDBB06797

P577

Q33485003-7D1CE08E-7615-4A4A-A2CD-8282ED2D5A36

P5875

Q33485003-AF5F6CA4-DE62-4898-9551-6A9217AB9B9A

P6179

Q33485003-FBA6EA6A-72BC-4CF7-8F23-D9EE0CCDFDB8

P698

Q33485003-2833D544-ECF9-4D99-A3AD-971011B87561

P921

Q33485003-B8031095-2366-4CC5-9818-4ABF63F2CA71

P932

Q33485003-AAA7F060-2A2C-4869-A237-AD6CEFEEA5BC

P356

1471-2407-9-249

P1433

P1476

Efficacy of sorafenib on metas ...... sults from a multicenter study

@en

P2093

Baijun Dong

http://www.w3.org/2001/XMLSchema#string

Bo Dai

http://www.w3.org/2001/XMLSchema#string

Dingwei Ye

http://www.w3.org/2001/XMLSchema#string

Hailiang Zhang

http://www.w3.org/2001/XMLSchema#string

Jiade J Lu

http://www.w3.org/2001/XMLSchema#string

Shilin Zhang

http://www.w3.org/2001/XMLSchema#string

Xudong Yao

http://www.w3.org/2001/XMLSchema#string

Yijun Shen

http://www.w3.org/2001/XMLSchema#string

Yiran Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.

Renal-cell carcinoma.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

P2888

1471-2407-9-249

P304

249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-249

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26685768

http://www.w3.org/2001/XMLSchema#string

P6179

1052229704

http://www.w3.org/2001/XMLSchema#string

P698

19622166

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2724546

http://www.w3.org/2001/XMLSchema#string